Myles David C.'s Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Nov 3, 2023
- Accession no.
- 0001415889-23-014792
- Filed
- Nov 3, 2023
- Trade date
- Nov 1-3, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $160.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Myles David C.CIK 0001831216 | Officer (CH. DISCOV. & NON-CLIN DEV OFF) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2023 | Common Stock | SSaleDisposed | −6,668 | $15.02 | −$100,153.36 | 565,343 | Direct | |
| Nov 2, 2023 | Common Stock | SSaleDisposed | −3,332 | $15.36 | −$51,179.52 | 562,011 | Direct | |
| Nov 3, 2023 | Common Stock | SSaleDisposed | −541 | $17.51 | −$9,472.91 | 561,470 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.